Equities

Zelira Therapeutics Ltd

Zelira Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.66
  • Today's Change-0.04 / -5.71%
  • Shares traded2.78k
  • 1 Year change-37.14%
  • Beta1.4332
Data delayed at least 20 minutes, as of Nov 11 2024 02:21 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of AUD
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments0.590.152.75
Total Receivables, Net2.15(0.01)0.25
Total Inventory1.251.531.96
Prepaid expenses0.110.100.12
Other current assets, total0.160.010.01
Total current assets4.261.775.08
Property, plant & equipment, net0.230.520.85
Goodwill, net03131
Intangibles, net0.650.810.97
Long term investments0.040.040.06
Note receivable - long term------
Other long term assets------
Total assets5.183438
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt3.5400
Current portion long-term debt/capital leases0.150.140.12
Other current liabilities, total------
Total current liabilities7.091.881.63
Total long term debt2.260.300.38
Total debt5.950.440.50
Deferred income tax------
Minority interest0.34(0.09)0.49
Other liabilities, total------
Total liabilities9.702.092.50
SHAREHOLDERS EQUITY
Common stock464644
Additional paid-in capital------
Retained earnings (accumulated deficit)(50)(13)(8.06)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.11)(0.57)(0.48)
Total equity(4.51)3235
Total liabilities & shareholders' equity5.183438
Total common shares outstanding11119.58
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.